Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in a webinar on April 29, 2021, featuring Dr. Heather Fehling from Clinical Reference Lab. The event will discuss PCR testing for COVID-19, highlighting non-invasive saliva tests and new applications in response to emerging strains. Co-Diagnostics’ technology is used in CRL's saliva PCR test, which boasts high sensitivity and specificity, with results typically available in 24 hours. This initiative aims to enhance testing accessibility and application in various settings.
Summary not available.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the successful use of its Logix Smart™ COVID-19 Test Kit by Australian researchers, with results published in the Journal of Medical Microbiology. The study showed analytical sensitivity of 1010 viral copies per ml, comparable to other tests used in Western Australia. The test performed well on clinical samples, demonstrating complete concordance with the comparison assay. CEO Dwight Egan emphasized the test's robustness and the company’s commitment to affordable molecular diagnostics in remote locations.
On March 31, 2021, Co-Diagnostics, Inc. CEO Dwight Egan discussed the company's FY2020 earnings on Yahoo! Finance, emphasizing the importance of at-home and point-of-care testing in achieving normalization post-COVID-19. He highlighted the development of a new platform aimed at quick and accurate COVID-19 testing, while emphasizing that continued testing will complement vaccine distribution. The company has established a global distributor network and is expanding its diagnostic product offerings, including liquid biopsy technology, to meet future demands.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported strong financial results for Q4 and full year 2020, driven largely by its Logix Smart™ COVID-19 Test. Fourth-quarter revenue reached $27.1 million with a gross profit margin of 84.1%, leading to a net income of $12.8 million, compared to a loss of $1.7 million in Q4 2019. For the full year, revenue soared to $74.6 million, a significant increase from the previous year, with net income of $42.5 million. The company anticipates ongoing demand for COVID-19 testing in 2021 and has initiated development of new testing platforms.
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close. The company will host a conference call and webcast at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson. Investors can access the live event via the company's website. For those unable to attend live, a recording will be made available later.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The presentation will cover the company's rapid PCR diagnostics platform supporting COVID-19 testing to help normalize daily routines. For registration details, visit the conference link. An archived version of the presentation will be available on the Co-Diagnostics website post-event. The company focuses on developing advanced molecular diagnostic tests using its proprietary technology.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced that CEO Dwight Egan will present at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference on March 11-12, 2021. Egan's presentation, scheduled for 12:10 pm ET on March 11, will cover the company's rapid PCR point-of-care and at-home testing platform for COVID-19 and other infectious diseases. This platform utilizes Co-Diagnostics' proprietary technology for enhanced testing efficiency. Attendees can register for the conference via the provided link.
Co-Diagnostics, Inc. (NASDAQ-CM: CODX) announced that CEO Dwight Egan will present at the 2021 H.C. Wainwright & Co. Global Life Sciences Conference, held virtually on March 9-10, 2021. Participants can register for the conference and access an archived version of the presentation on the company's website. Co-Diagnostics develops and markets advanced molecular diagnostic technology, focusing on tests that analyze nucleic acids. The company emphasizes its ongoing expansion and the potential for increased sales and distribution of its innovative liquid biopsy tests.
Co-Diagnostics, Inc. (Nasdaq: CODX) introduced a new PCR diagnostic testing platform for Covid-19 suitable for businesses, schools, and homes. This compact device employs a Direct Saliva extraction-free protocol to provide rapid results via a smartphone app. Designed for accessibility, this platform aims to augment traditional testing methods, allowing for affordable, accurate surveillance. Co-Diagnostics plans to expand the device's capabilities to include testing for other pathogens, with regulatory submission expected later this year.